Background: Hepatic arterial infusion (HAI) of chemotherapy is a treatment option for patients (pts) with cancer metastatic to the liver. We investigated HAI oxaliplatin combined with capecitabine +/- bevacizumab, in advanced cancer with liver involvement. Methods: Pts received HAI oxaliplatin (140 mg/m²) and escalating doses of capecitabine (500, 750, and 1000 mg/m²), with (Arm A) or without (Arm B) bevacizumab (10 mg/kg IV). A 3+3 dose design was used, followed by an expansion phase. Results: From 9/2009 to 2/2014, 61 pts (34 men, 27 women) were enrolled (Arm A = 44; Arm B = 17). Pts were treated in Arm B if they had contraindications to bevacizumab (n = 13) or if there was no spot available in Arm A (n = 4). The median age was 60 yrs (range, 20-88). The most common cancers were colorectal (22 pts), liver (13), pancreas (7), breast (4), and biliary tract (4). The median number of prior therapies was 3 (range, 1-12); 32 (53%) pts had previously oxaliplatin. Grade 3 diarrhea was the only DLT and occurred in 2 pts receiving 1000 mg/m² capecitabine. Thus, the MTD was HAI oxaliplatin 140 mg/m², capecitabine 750 mg/m², and bevacizumab 10 mg/kg. Common toxicities were anemia, thrombocytopenia, neutropenia, hypomagnesemia, and nausea/vomiting. Outcomes are shown in Table. Eleven (18%) pts remained on treatment for ≥6 months, including 4 (6.6%) pts who remained on treatment for ≥1 year. Conclusions: HAI oxaliplatin combined with capecitabine +/- bevacizumab was well-tolerated and was associated with favorable outcomes in selected pts. Clinical trial information: NCT01213238

* CR complete response, OS: overall survival, PR: partial response, Rx: treatment, SD: stable disease, TTF: time to treatment failure